Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

260
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
260
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

796
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

204
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
204
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

163
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
163
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

273
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
273

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Sex Differences in Clinical Outcomes and Loss of Life Expectancy After Aortic Valve Surgery for Infective Endocarditis: A SWEDEHEART Study.

Journal of the American Heart Association·2026
Same author

Oxylipin-mediated metabolic signatures of symbiosis homeostasis and thermal stress in a model sea anemone.

The ISME journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

LIPID MAPS: Powering discovery in lipidomics.

Science signaling·2026

相关实验视频

Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K

欧米茄3多不和脂肪酸通过Resolvin E1和ChemR23轴降低大动脉膜疾病

Gonzalo Artiach1, Miguel Carracedo1, Oscar Plunde1

  • 1Department of Medicine (G.A., M.C., O.P., S.T., A.L.-F., H.A., M.B.), Karolinska Institutet, Stockholm, Sweden.

Circulation
|June 9, 2020
PubMed
概括
此摘要是机器生成的。

欧米茄-3 脂肪酸 (n-3 PUFA) 和它们的调解素E1 抑制了大动脉狭窄 (AVS) 的进展. 针对这种途径可能为AVS提供新的治疗选择.

关键词:
化,生理上的脂肪酸,欧米茄三类心脏膜疾病炎症的发生脂质

更多相关视频

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

相关实验视频

Last Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

科学领域:

  • 心血管生物学
  • 脂质组学
  • 炎症研究

背景情况:

  • 大动脉狭窄 (AVS) 是最常见的气性心脏病,其特征是大动脉变厚和化.
  • 欧米茄3多不和脂肪酸 (n-3PUFA) 对心血管有好处,并且是具有抗炎性质的专用前溶媒的前体.
  • 在AVS的发病过程中,n-3PUFA及其衍生媒介的作用在很大程度上仍未确定.

研究的目的:

  • 调查n-3PUFA衍生的专用预溶媒体在AVS发展中的作用.
  • 要确定是否有影响于主动脉的化.

主要方法:

  • 人类大动脉的脂质和转录分析.
  • 在机械研究中使用了Apoe-/-小鼠和电线损伤模型.
  • 研究了内源性n-3PUFA合成和resolvin E1受体 (ChemR23) 活性的影响.

主要成果:

  • 人类静脉的非化区域比化区域的n-3PUFA合量更高.
  • 在化区域中,Resolvin E1的调节失调,并抑制了化.
  • 具有增强内源性n-3PUFA合成的小鼠表现出降低了膜化和改善心脏功能.
  • 阻断溶解素E1受体消除了这些有益作用.

结论:

  • 在抑制AVS进展方面,由n-3PUFA衍生的resolvin E1及其受体ChemR23轴至关重要.
  • 这一途径代表了AVS患者的潜在新疗法标.